Published in CMAJ on February 08, 2006
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Waking up from the DREAM of preventing diabetes with drugs. BMJ (2007) 0.94
Thiazolidinediones: a 2010 perspective. Perm J (2010) 0.88
Protocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials. J Res Med Sci (2012) 0.76
Rosiglitazone and macular edema. CMAJ (2006) 0.75
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ (2002) 1.64
Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol (2005) 1.60
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
Herbal kava: reports of liver toxicity. CMAJ (2002) 2.17
Concerns over lindane treatment for scabies and lice. CMAJ (2003) 2.01
Droperidol: cardiovascular toxicity and deaths. CMAJ (2002) 1.68
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ (2002) 1.64
Cochlear implant recipients at risk for meningitis. CMAJ (2002) 1.61
A catalyst for change. CMAJ (2006) 1.48
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ (2004) 1.43
Alcohol-associated rapid release of a long-acting opioid. CMAJ (2005) 1.42
Congratulations to our colleagues at Open Medicine. CMAJ (2007) 1.39
Brief safety updates: acetaminophen, ASA and kava. CMAJ (2002) 1.38
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ (2005) 1.29
Too much of a good thing? Toxic effects of vitamin and mineral supplements. CMAJ (2003) 1.27
Propofol: contraindicated for sedation of pediatric intensive care patients. CMAJ (2002) 1.25
Diane-35 (cyproterone acetate): safety concerns. CMAJ (2003) 1.22
Pharmaceutical industry representation on CIHR's governing council. Open Med (2010) 1.20
Open Medicine is indexed in PubMed. Open Med (2010) 1.18
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ (2002) 1.18
Open science, open access and open source software at Open Medicine. Open Med (2008) 1.06
Paroxetine (Paxil) and congenital malformations. CMAJ (2005) 1.03
No budget, no worries: Free and open source publishing software in biomedical publishing. Open Med (2008) 1.00
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ (2002) 0.99
Salmeterol (Serevent) asthma trial halted early. CMAJ (2003) 0.99
Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ (2004) 0.97
Cervical cancer screening among HIV-positive women. Retrospective cohort study from a tertiary care HIV clinic. Can Fam Physician (2010) 0.95
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ (2005) 0.93
Tamoxifen for breast cancer prevention: safety warning. CMAJ (2002) 0.92
Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ (2002) 0.90
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ (2002) 0.90
Facts on mercury and fish consumption. CMAJ (2002) 0.88
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. CMAJ (2003) 0.88
Visual loss with erectile dysfunction medications. CMAJ (2006) 0.88
Ephedra/ephedrine: cardiovascular and CNS effects. CMAJ (2002) 0.88
HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ (2002) 0.87
Noninvasive treatments for umbilical granulomas. Am Fam Physician (2003) 0.85
Open Medicine endorses PROSPERO. Open Med (2011) 0.85
Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001-2011. J Acquir Immune Defic Syndr (2015) 0.84
Long-acting beta2-agonists in asthma: safety concerns. CMAJ (2005) 0.84
Suicidal ideation among children taking atomoxetine (Strattera). CMAJ (2005) 0.83
Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ (2007) 0.83
Failure of rapid HIV tests. CMAJ (2002) 0.83
Accutane (isotretinoin) and psychiatric adverse effects. CMAJ (2003) 0.83
People with diabetes should avoid antibiotic gatifloxacin. CMAJ (2006) 0.82
Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. CMAJ (2005) 0.82
Striving for excellence: developing a framework for the Triple C curriculum in family medicine education. Can Fam Physician (2012) 0.82
The Canadian Hypertension Education Program (CHEP) recommendations: launching a new series. CMAJ (2005) 0.82
Infliximab and serious hematologic events. CMAJ (2004) 0.80
Medications for attention deficit hyperactivity disorder: cardiovascular concerns. CMAJ (2006) 0.80
Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders. CMAJ (2002) 0.79
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ (2005) 0.79
Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ (2004) 0.79
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. CMAJ (2005) 0.78
Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ (2004) 0.78
HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ (2004) 0.78
Nephrology in practice: a new series. CMAJ (2002) 0.77
Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ (2004) 0.76
Osteoporosis treatment: raloxifene (Evista) and stroke mortality. CMAJ (2006) 0.76
Reporting test results directly to patients: is there anything to lose? Open Med (2011) 0.75
Prisons and public health. Open Med (2011) 0.75
Serious allergic reactions following tuberculin skin tests. CMAJ (2005) 0.75
Earlier clinical conundrum resolved: a diagnosis with teeth. CMAJ (2005) 0.75
Opening Pandora's box: the public declaration of competing interests. Open Med (2010) 0.75
Socioeconomic status and allied health use: Among patients in an academic family health team. Can Fam Physician (2016) 0.75
Perspectives of People Living with HIV on Access to Health Care: Protocol for a Scoping Review. JMIR Res Protoc (2016) 0.75
Meniscus. CMAJ (2002) 0.75
Combination hormone replacement therapy and dementia. CMAJ (2003) 0.75
Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ (2006) 0.75
Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ (2006) 0.75
Nail gun. CMAJ (2002) 0.75
Is the timing of infant cereal introduction a risk factor for celiac disease autoimmunity? CMAJ (2005) 0.75
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ (2005) 0.75
Hua Fo tablets tainted with sildenafil-like compound. CMAJ (2002) 0.75
Up close and personal: poverty and human development. Open Med (2007) 0.75
Ototoxic effects from gentamicin ear drops. CMAJ (2002) 0.75
WinRho and disseminated intravascular coagulopathy. CMAJ (2006) 0.75
Several Chinese herbal products may contain toxic aristolochic acid. CMAJ (2004) 0.75
Fostering excellence: roles, responsibilities, and expectations of new family physician clinician investigators. Can Fam Physician (2014) 0.75
Open Medicine at five years. Open Med (2012) 0.75
Medical gels and the risk of serious infection. CMAJ (2004) 0.75
Patient information about HPV and the HPV vaccine. CMAJ (2007) 0.75
Epoetin alfa (Eprex): reports of pure red blood cell aplasia. CMAJ (2002) 0.75
Leaders or followers? It's time for health faculty to open up. Open Med (2008) 0.75
Does a short course of clarithromycin affect mortality in patients with stable coronary artery disease? CMAJ (2006) 0.75
The use of multistate models to examine associations of stress and adherence with transitions among HIV care states observed in a clinical HIV cohort. J Acquir Immune Defic Syndr (2017) 0.75